About ORBUSNEICH Company

We are a leading global PCI/PTA balloon developer and manufacturer. The company is headquartered in Hong Kong, China, and our products are sold to more than 70 countries and regions around the world. In addition to PCI/PTA balloons, we also specialize in coronary stent products and are actively expanding our business into the fields of neurovascular intervention and structural heart disease. The Group's history can be traced back to 2000, when our honorary chairman and founder, Mr. Qian Xuexiong, started our cardiovascular interventional medical device business. Mr. Qian Xuexiong has been working in medicine for the past 50 years, holding various positions in pharmaceutical and medical device companies. Mr. Qian Xuexiong first founded Cordis Neich for Cordis Corporation in Asia, an exclusive distributor of diagnostic and interventional medical devices. After the assets of Cordis Corporation and Cordis Neich were acquired by Johnson & Johnson in 1996, Qian Xuexiong first formed the capital group, which focused on the development and manufacture of endovascular interventional devices. Mr. Qian Xuexiong also founded the Chien Foundation, which aims to provide young interventional cardiologists with financial resources and training opportunities related to advanced techniques in interventional cardiology. Its overall goal is to improve the level of medical care and benefit the public in Asia-Pacific countries. Under Mr. Qian Xuexiong's leadership, we acquired Orbus Medical Technologies Inc (mainly focused on the development and production of stents) through mergers and acquisitions in 2005, further expanding our R&D and production capacity. Mr. Qian Yongxun became our CEO in 2016. Under the leadership of Mr. Qian Yongxun, the Group rapidly expanded its business by expanding the market, strengthening market penetration, enriching the product portfolio, and expanding new business areas. In 2021, the Group opened up investment to third parties for the first time and successfully raised more than 200 million US dollars, marking a new chapter in the Group's development.